Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

Breast

Volumn 19, Issue 2, 2010, Pages 92-96

  Hines, Stephanie L ^a   Sloan, Jeff A ^b   Atherton, Pamela J ^b   Perez, Edith A ^a   Dakhil, Shaker R ^c   Johnson, David B ^c   Reddy, Pavan S ^c   Dalton, Robert J ^d   Mattar, Bassam I ^c   Loprinzi, Charles L ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

^c Wichita Community Clinical Oncology   (United States)

^d ALBERT LEA EYE CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CALCIUM; LETROZOLE; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HOT FLUSH; HUMAN; JAW OSTEONECROSIS; LIFE EXPECTANCY; LUMBAR SPINE; MAJOR CLINICAL STUDY; NAUSEA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; SIDE EFFECT; VOMITING;

EID: 77951208814     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.12.001     Document Type: Article

References (25)

1. Perez E.A., Weilbaecher K. Aromatase inhibitors and bone loss. Oncology 2006, 20(9):1029-1039.
2. Prince R.L., Smith M., Dick I.M., Price R.I., Webb P.G., Henderson N.K., et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone replacement therapy. NEJM 1991, 325(17):1189-1195.
3. Riis B., Thomsen K., Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. NEJM 1987, 316(4):173-177.
4. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
5. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004 Apr 14, 291(14):1701-1712.
6. Powles T., Hickish T., Kanis J.A., Tidy A., Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996, 14(1):78-84.
7. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopasual women with primary breast cancer. NEJM 2004, 350(11):1081-1092.
8. The A.T.A.C. Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002, 359:2131-2139.
9. The A.T.A.C. Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
10. Coates A.S. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007, 25(5):486-492.
11. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007, 369:559-570.
12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from the NCIC CTG MA.17. JNCI 2005, 97(17):1262-1271.
13. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination trial. J Bone Mineral Res 2006, 21(8):1215-1223.
14. Perez E.A., Josse R.G., Pritchard K.I., Ingle J.N., Martino S., Findlay B.P., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24(22):3629-3635.
15. Brufsky A., Harker W.G., Beck J.T., Carroll R., Tan-Chiu E., Seidler C., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25(7):829-836.
16. Reid I.R., Brown J.P., Burckhardt P., Horowitz A., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. NEJM 2002, 346(9):653-661.
17. Hines S.L., Mincey B.A., Dentchev T., Sloan J.A., Perez E.A., Johnson D.B., et al. Immediate vs. delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen. Breast Cancer Res Treat 2009, DOI 10.1007/s10549-009-0332-2.
18. Cummings S.R., Black D.M., Nevitt M.C., Browner W., Cauley J., Ensrud K., et al. Bone density at various sites for prediction of hip fractures. Lancet 1993, 341:72-75.
19. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19(4):385-397.
20. Harrington J.T., Ste-Marie L.G., Brandi M.L., Civitelli R., Fardellone P., Grauer A., et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 74:129-135.
21. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M.D., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom 2004, 7(3):255-261.
22. Crandall C. Risedronate: a clinical review. Arch Intern Med 2001, 161:353-360.
23. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998, 280(24):2077-2082.
24. Van Poznak C., Hannon R.A., Clack G., Campone M., Mackey J.R., Apffelstaedt J., et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: 12-month analysis. Breast Cancer Res Treat 2007, 106(Supple 1):S37. (abstract 502).
25. Lester J.E., Dodwell D., Purohit O.P., Gutcher S.A., Ellis S.P., Thorpe R., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14(19):6336-6342.